Teladoc Health opened lower at $8.82, compared with its previous close of $8.94. In the last trading session, the stock traded between $8.64 and $8.94. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Teladoc Health is now worth
$ 6.41
Resulting in a loss of
$ 93.59 (93.59%)
Note: Past profits do not guarantee future returns.
Rating from 15 Analysts
Today's Change
$-0.25 (-2.74%)
Day High
$8.94
Day Low
$8.64
Day Open
$8.82
Prev Close
$8.94
Volume
24,63,637
1W Return
-10.29%
1M Return
46.75%
3M Return
27.79%
6M Return
25.65%
1Y Return
15.01%
Market Cap ($ Mn)
1,585
PE Ratio
-
PB Ratio
0.90
PEG Ratio
-
ROE
-14.07%
ROCE
-10.11%
EPS (TTM)
$-0.15
1 Week
-10.29%
1 Month
46.75%
3 Months
27.79%
6 Months
25.65%
9 Months
85.79%
TD Cowen raises Teladoc Health price target to $8, maintains Hold
TD Cowen raised Teladoc Health's price target to $8 from $6. Rating maintained at Hold by analyst Charles Rhyee. Follows target increases from Barclays, UBS, and Oppenheimer. Broker targets now range from $8 to $10.
3 days agoTeladoc Health to report Q3 2026 results on October 28
Teladoc Health releases Q3 2026 results on October 28, 2026. Conference call scheduled for 5:00 pm ET same day. Replay available for 90 days post-call.
29 days agoTeladoc grants Michael Grasher 239,616 RSUs and PSUs as CFO inducement
Teladoc Health granted Michael Grasher 239,616 RSUs and target PSUs upon starting as CFO. Performance units can yield up to 479,232 shares based on 2026 EBITDA and 2026-2028 revenue growth. Awards were approved by the Compensation Committee under NYSE Rule 303A.08. RSUs vest over time based on continued service, starting one year after the grant date.
2mo agoTeladoc Health stock falls 38% as firm cuts FY26 revenue guidance
Teladoc Health stock fell 38.32% to close at $6.58 per share on July 30, 2026. Company cut full-year 2026 revenue guidance to $2.36-$2.45 billion from $2.48-$2.58 billion. BetterHelp platform faces pressure from insurance preference shifts and cash pay decline. Pomerantz LLP investigates potential securities fraud claims against Teladoc.
2mo agoPomerantz LLP expands Teladoc fraud probe after Q2 miss and stock plunge
Pomerantz LLP joined three other firms in investigating Teladoc Health for securities fraud after a 38% stock plunge on July 30, 2026. The drop followed a Q2 revenue miss of $606.9 million and a full-year guidance cut to $2.36-$2.45 billion, driven by declines in the BetterHelp segment. Investors with losses from July 2025 to July 29, 2026, are urged to contact the firm.
2mo agoHalper Sadeh probes Teladoc Health insiders for fiduciary duty breach
Halper Sadeh LLC is probing Teladoc Health insiders for alleged fiduciary duty breaches. Long-term shareholders may seek governance reforms or financial relief through a contingent fee arrangement. The firm urges immediate contact to enforce rights.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $506.04 | +0.32% | $1,05,708.21M | 14.01 | |
| $304.77 | -0.26% | $49,345.01M | 45.36 | |
| $292.97 | +0.93% | $23,316.90M | 10.31 | |
| $72.62 | +0.18% | $14,450.29M | 52.31 | |
| $79.43 | -1.38% | $14,087.55M | - | |
| $142.24 | -0.19% | $13,957.16M | 20.21 | |
| $22.22 | -2.29% | $11,935.03M | 11.93 | |
| $183.50 | +2.35% | $11,542.15M | 15.26 | |
| $186.19 | +0.59% | $10,862.51M | 27.11 | |
| $196.77 | +0.70% | $10,170.65M | 7.00 | |
| $103.03 | -0.49% | $8,522.13M | 34.79 | |
| $50.06 | +1.96% | $7,945.72M | 25.00 |
An investment of $100 made 5 years ago in Teladoc Health is now worth
$ 6.41
Resulting in a loss of
$ 93.59 (93.59%)
Note: Past profits do not guarantee future returns.
